WAVE1 mediates suppression of phagocytosis by phospholipid-derived DAMPs

Journal of Clinical Investigation

Volumn 123, Issue 7, 2013, Pages 3014-3024

  Matt, Ulrich ^a,b,d   Sharif, Omar ^a,b   Martins, Rui ^a,b   Furtner, Tanja ^a,b,e   Langeberg, Lorene ^c   Gawish, Riem ^a,b   Elbau, Immanuel ^a,b   Zivkovic, Ana ^a,b   Lakovits, Karin ^b   Oskolkova, Olga ^b   Doninger, Bianca ^a,b   Vychytil, Andreas ^b   Perkmann, Thomas ^b   Schabbauer, Gernot ^b   Binder, Christoph J ^a,b   Bochkov, Valery N ^b   Scott, John D ^c   Knapp, Sylvia ^a,b  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

OXIDIZED PHOSPHOLIPID; PHOSPHOLIPID; REGULATOR PROTEIN; UNCLASSIFIED DRUG; WAVE 1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL PERITONITIS; CONTROLLED STUDY; DANGER ASSOCIATED MOLECULAR PATTERN; ESCHERICHIA COLI; GENE SILENCING; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO CULTURE; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; PERITONEAL DIALYSIS; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; CELL LINE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIMYRISTOYLPHOSPHATIDYLCHOLINE; ENZYME ACTIVATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; IMMUNITY, INNATE; KIDNEY FAILURE, CHRONIC; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATION-REDUCTION; PERITONEAL DIALYSIS; PERITONITIS; PHAGOCYTOSIS; PHOSPHATIDYLCHOLINES; PHOSPHOLIPIDS; WISKOTT-ALDRICH SYNDROME PROTEIN FAMILY;

EID: 84879663616     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI60681     Document Type: Article

References (68)

1. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood. 1998;92(9):3007-3017. (Pubitemid 28492304)
2. Miller YI, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res. 2011;108(2):235-248.
3. Binder CJ, et al. Innate and acquired immunity in atherogenesis. Nat Med. 2002;8(11):1218-1226. (Pubitemid 35373552)
4. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6(7):508-519. (Pubitemid 43980523)
5. Yoshimi N, et al. Oxidized phosphatidylcholine in alveolar macrophages in idiopathic interstitial pneumonias. Lung. 2005;183(2):109-121. (Pubitemid 41264740)
6. Nakamura T, Henson PM, Murphy RC. Occurrence of oxidized metabolites of arachidonic acid esterified to phospholipids in murine lung tissue. Anal Biochem. 1998;262(1):23-32. (Pubitemid 28440683)
7. Imai Y, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133(2):235-249. (Pubitemid 351512299)
8. Matt U, et al. Bbeta(15-42) protects against acid-induced acute lung injury and secondary pseudomonas pneumonia in vivo. Am J Respir Crit Care Med. 2009;180(12):1208-1217.
9. Newcombe J, Li H, Cuzner ML. Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: implications for pathogenesis. Neuropathol Appl Neurobiol. 1994;20(2):152-162. (Pubitemid 24123546)
10. Dei R, et al. Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease. Acta Neuropathol. 2002;104(2):113-122. (Pubitemid 36075368)
11. Bochkov VN, Kadl A, Huber J, Gruber F, Binder BR, Leitinger N. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature. 2002;419(6902):77-81. (Pubitemid 34987873)
12. Knapp S, Matt U, Leitinger N, van der Poll T. Oxidized phospholipids inhibit phagocytosis and impair outcome in gram-negative sepsis in vivo. J Immunol. 2007;178(2):993-1001. (Pubitemid 46095173)
13. Cruz D, et al. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest. 2008;118(8):2917-2928.
14. Holzheimer RG, Muhrer KH, L'Allemand N, Schmidt T, Henneking K. Intraabdominal infections: classification, mortality, scoring and pathophysiology. Infection. 1991;19(6):447-452.
15. Wickel DJ, Cheadle WG, Mercer-Jones MA, Garrison RN. Poor outcome from peritonitis is caused by disease acuity and organ failure, not recurrent peritoneal infection. Ann Surg. 1997;225(6):744-753.
16. Pinheiro da Silva F, et al. CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nat Med. 2007;13(11):1368-1374.
17. Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in action. Annu Rev Immunol. 2002;20:825-852. (Pubitemid 34293441)
18. Takenawa T, Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol. 2007;8(1):37-48. (Pubitemid 46012013)
19. Westphal RS, Soderling SH, Alto NM, Langeberg LK, Scott JD. Scar/WAVE-1, a Wiskott-Aldrich syndrome protein, assembles an actin-associated multi-kinase scaffold. Embo J. 2000;19(17):4589-4600.
20. Dinh H, Scholz GM, Hamilton JA. Regulation of WAVE1 expression in macrophages at multiple levels. J Leukoc Biol. 2008;84(6):1483-1491. (Pubitemid 352774483)
21. Friedman P, Horkko S, Steinberg D, Witztum JL, Dennis EA. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J Biol Chem. 2002;277(9):7010-7020. (Pubitemid 34953088)
22. Kaksonen M, Toret CP, Drubin DG. Harnessing actin dynamics for clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2006;7(6):404-414. (Pubitemid 44050094)
23. Miller YI, Worrall DS, Funk CD, Feramisco JR, Witztum JL. Actin polymerization in macrophages in response to oxidized LDL and apoptotic cells: role of 12/15-lipoxygenase and phosphoinositide 3-kinase. Mol Biol Cell. 2003;14(10):4196-4206. (Pubitemid 37186320)
24. Park YM, Febbraio M, Silverstein RL. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J Clin Invest. 2009;119(1):136-145.
25. Boullier A, et al. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem. 2000;275(13):9163-9169. (Pubitemid 30185132)
26. Li R, et al. Identification of prostaglandin E2 receptor subtype 2 as a receptor activated by OxPAPC. Circ Res. 2006;98(5):642-650.
27. Birukova AA, Chatchavalvanich S, Oskolkova O, Bochkov VN, Birukov KG. Signaling pathways involved in OxPAPC-induced pulmonary endothelial barrier protection. Microvasc Res. 2007;73(3):173-181. (Pubitemid 46604761)
28. Walton KA, et al. Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol. 2003;23(7):1197-1203. (Pubitemid 36871273)
29. Seyerl M, et al. Oxidized phospholipids induce anergy in human peripheral blood T cells. Eur J Immunol. 2008;38(3):778-787.
30. Levitan I, Gooch KJ. Lipid rafts in membrane-cytoskeleton interactions and control of cellular biomechanics: actions of oxLDL. Antioxid Redox Signal. 2007;9(9):1519-1534. (Pubitemid 47260439)
31. Birukov KG, et al. Epoxycyclopentenone-containing oxidized phospholipids restore endothelial barrier function via Cdc42 and Rac. Circ Res. 2004;95(9):892-901. (Pubitemid 39435004)
32. Bryn T, Mahic M, Enserink JM, Schwede F, Aandahl EM, Tasken K. The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. J Immunol. 2006;176(12):7361-7370. (Pubitemid 43849037)
33. Scott JD, Fischer EH, Demaille JG, Krebs EG. Identification of an inhibitory region of the heat-stable protein inhibitor of the cAMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1985;82(13):4379-4383. (Pubitemid 15234239)
34. Scott JD, Glaccum MB, Fischer EH, Krebs EG. Primary-structure requirements for inhibition by the heat-stable inhibitor of the cAMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1986;83(6):1613-1616. (Pubitemid 16018614)
35. Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc Drug Rev. 2006;24(3-4):261-274. (Pubitemid 46435008)
36. Cheng HC, et al. A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase. J Biol Chem. 1986;261(3):989-992. (Pubitemid 16144753)
37. Kim C, Xuong NH, Taylor SS. Crystal structure of a complex between the catalytic and regulatory (RIalpha) subunits of PKA. Science. 2005;307(5710):690-696. (Pubitemid 40194632)
38. Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev. 2004;84(1):137-167. (Pubitemid 38049878)
39. Scott JD, Pawson T. Cell signaling in space and time: where proteins come together and when they're apart. Science. 2009;326(5957):1220-1224.
40. Carr DW, Hausken ZE, Fraser ID, Stofko-Hahn RE, Scott JD. Association of the type II cAMP-dependent protein kinase with a human thyroid RII-anchoring protein. Cloning and characterization of the RII-binding domain. J Biol Chem. 1992;267(19):13376-13382.
41. Soderling SH, et al. Loss of WAVE-1 causes sensorimotor retardation and reduced learning and memory in mice. Proc Natl Acad Sci U S A. 2003;100(4):1723-1728. (Pubitemid 36254515)
42. Murch AR, Grounds MD, Papadimitriou JM. Improved chimaeric mouse model confirms that resident peritoneal macrophages are derived solely from bone marrow precursors. J Pathol. 1984;144(2):81-87. (Pubitemid 15202420)
43. Krediet RT, Balafa O. Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol. 2010;6(8):451-460.
44. Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr Opin Nephrol Hypertens. 2003;12(6):593-598. (Pubitemid 38186749)
45. Oberg BP, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65(3):1009-1016. (Pubitemid 38251077)
46. Troidle L, Finkelstein F. Treatment and outcome of CPD-associated peritonitis. Ann Clin Microbiol Antimicrob. 2006;5:6.
47. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000;58(4):1758-1764.
48. Palinski W, et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 1996;98(3):800-814. (Pubitemid 26349186)
49. Chang MK, et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci U S A. 1999;96(11):6353-6358.
50. Soderling SH, et al. A WAVE-1 and WRP signaling complex regulates spine density, synaptic plasticity, and memory. J Neurosci. 2007;27(2):355-365. (Pubitemid 46106009)
51. Kim Y, et al. Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology. Nature. 2006;442(7104):814-817. (Pubitemid 44258911)
52. Cameron JS. Host defences in continuous ambulatory peritoneal dialysis and the genesis of peritonitis. Pediatr Nephrol. 1995;9(5):647-662.
53. Kato S, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3(5):1526-1533.
54. Muller LM, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41(3):281-288. (Pubitemid 41022101)
55. Jager KJ, et al. Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link? Kidney Int Sup. 2011;1:21-23.
56. Latcha S, Hong S, Gibbons N, Kohn N, Mattana J. Relationship between dialysate oxidized protein and peritoneal membrane transport properties in patients on peritoneal dialysis. Nephrol Dial Transplant. 2008;23(10):3295-3301.
57. Posthuma N, ter Wee P, Donker AJ, Dekker HA, Oe PL, Verbrugh HA. Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients. Perit Dial Int. 1999;19(4):334-342. (Pubitemid 30011696)
58. Poyrazoglu HM, Dusunsel R, Patiroglu T, Gunduz Z, Utas C, Gunes T. Humoral immunity and frequency of peritonitis in chronic peritoneal dialysis patients. Pediatr Nephrol. 2002;17(2):85-90. (Pubitemid 36067976)
59. Horkko S, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid- protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999;103(1):117-128. (Pubitemid 29031170)
60. Subbanagounder G, et al. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1β. J Biol Chem. 2002;277(9):7271-7281. (Pubitemid 34953120)
61. Maier S, et al. Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock. 2004;21(6):505-511.
62. Bosmann M, Russkamp NF, Patel VR, Zetoune FS, Sarma JV, Ward PA. The outcome of polymicrobial sepsis is independent of T and B cells. Shock. 2011;36(4):396-401.
63. Reim D, Westenfelder K, Kaiser-Moore S, Schlautkotter S, Holzmann B, Weighardt H. Role of T cells for cytokine production and outcome in a model of acute septic peritonitis. Shock. 2009;31(3):245-250.
64. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Invest. 2003;112(4):460-467. (Pubitemid 38056327)
65. Hoebe K, et al. CD36 is a sensor of diacylglycerides. Nature. 2005;433(7025):523-527. (Pubitemid 40204309)
66. Pawlinski R, et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood. 2004;103(4):1342-1347. (Pubitemid 38168646)
67. Carpenter AE, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006;7(10):R100.
68. Lagler H, et al. TREM-1 activation alters the dynamics of pulmonary IRAK-M expression in vivo and improves host defense during pneumococcal pneumonia. J Immunol. 2009;183(3):2027-2036.